In vivo efficacy of the tumor growth inhibition of the new HER3-targeting affibody constructs 3A and 33A was compared with the previously evaluated construct 3A3 and the anti-HER3 antibody MM-121 in mice bearing HER3-expressing BxPC-3 xenografts (Figure 2A). The gene discussed is ERBB3; the disease is neoplasm.